In accordance with Section 3 of the Articles of Association of Orion Corporation, 38,220 A shares have been converted into 38,220 B shares. The conversion has been entered into the Trade Register on 1 February 2022.
The total number of shares in Orion Corporation is 141,134,278 which, after the conversion, consists of 34,774,986 A shares and 106,359,292 B shares. The number of votes of the company's shares is after the conversion 801,859,012.
| Jari Karlson|
| Olli Huotari|
SVP, Corporate Functions
Tuukka Hirvonen, Investor Relations, tel. +358 10 426 2721
Orionintie 1A, FI-02200 Espoo, Finland
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are neurological disorders, oncology and respiratory diseases for which Orion develops inhaled pulmonary medication. Orion's net sales in 2020 amounted to EUR 1,078 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.